The FDA last week approved...

...Novartis' Cosentyx for the treatment of non-radiographic axial spondyloarthritis in adult patients. Cosentyx is the second IL-17 inhibitor to earn this status in a matter of weeks, coming in just behind Eli Lilly's Taltz, cementing the two drugs' rival status. For the treatment of ankylosing spondylitis, Cosentyx holds preferred status for 2% of covered lives under the pharmacy benefit, growing to 40% with prior authorization and/or step therapy. Meanwhile, in the same indication the Taltz autoinjector holds preferred status for less than 1% of covered lives, growing to 10% with PA/ST.

SOURCE: MMIT Analytics, as of 6/17/20